Send us a text

The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.

In this episode onSurfing NASH , Jörn Schattenberg, Louise Campbell and Roger Green review this recently concluded meeting with faculty members Sven Francque and Hannes Hagström. Jörn joins both guests as a fellow presenter and the group dives into program highlights with many fascinating takes and interplaying ideas. 

The first featured interview is with Sven, who served as one of three organizing members for this year's Summit. In addition, Sven chaired both the opening and closing Plenary sessions on the subject of Metabolism, Alcohol and Toxicity. Sven also delivered a presentation titled Anti-platelet drugs in MASLD: pre-clinical and clinical data. The following feature with Hannes explores elements of his presentation on how common alcohol overconsumption is in MASLD and how highly this increases risk for future cirrhosis. Throughout both interviews, Jörn is able to elaborate and reflect on his high level of engagement at the Summit as he chaired an industry session and gave three presentations with subjects ranging from clinical trial data (MAESTRO-NASH for resmetirom) to endoscopic bariatric therapies and mitochondrial uncoupling.

With that, listen to the full episode to gain a richer understanding than can be described in this summary. If you have questions or comments around the Summit or any other themes addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].

From the official EASL SLD Summit website:

The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD. You will gain insights in the most key techniques employed in research, clinical trials and clinical practice, with an understanding of their potential as well as limitations. You will learn about the most recent advances in our understanding of the disease, including the role of sexual dimorphism, circadian clock or vascular mechanisms, and potential new targets as well as modalities of treatment. You will exchange on these topics with both young fellows and established experts in the field in a highly interactive format with a lot of room for discussion. You will get the latest update on where we stand with the efforts of having MASLD, and SLD in general, on the agenda as a public health problem and the roadmap and policies to tackle this problem, in which the people living with SLD, and many stakeholders have been increasingly joining forces. In light of the latter, the Summit will also provide a space to further discuss the nomenclature change and its potential impact on research clinical practice and awareness. A session will be dedicated to discussing in-depth the issue of people who combine alcohol use and metabolic risk factors, designated as MetALD in the latest nomenclature. You will also get the latest data on diagnosis and prognostication in MASH and on how to tackle MASLD as a multisystem disease, informing you n